Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.63 |
| ▸ | THRA | P10827 | 4/20 | 0.63 |
| ▸ | THRB | P10828 | 4/20 | 0.63 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.63 |
| ▸ | ASPH | Q12797 | 1/20 | 0.63 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.63 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.63 |
| ▸ | EGLN2 | Q96KS0 | 12/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4551499 | 0.91 | EGLN1 (0.53) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL30401668 | 0.91 | EGLN1 (0.55) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL4551839 | 0.86 | EGLN1 (0.53) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL16280563 | 0.85 | EGLN1 (0.68) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL14672078 | 0.85 | EGLN1 (0.71) | EGLN1THRATHRBBBOX1SLC6A2 | |
| Acetic Acid SCHEMBL30394209 | 0.83 | EGLN1 (0.65) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL14941692 | 0.83 | EGLN1 (0.50) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL31267308 | 0.82 | EGLN1 (0.70) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL29046746 | 0.82 | EGLN1 (0.67) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL14672080 | 0.82 | EGLN1 (0.70) | EGLN1THRATHRBBBOX1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3003284-A1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | Fibrogen, Inc. (US) | 2016-04-13 | — | — | EP | claimed |
| WO-2014197660-A1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | FIBROGEN, INC. (US) | 2014-12-11 | — | — | WO | claimed |
| WO-2025029611-A1 | THERAPIES FOR DISEASES OF COPPER METABOLISM | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2025-02-06 | — | — | WO | disclosed |
| CN-117999069-A | Pediatric formulation of ferric citrate | 凯克斯生物制药公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-4347022-A1 | PEDIATRIC FORMULATIONS OF FERRIC CITRATE | Keryx Biopharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4138825-A1 | TREATMENT OF VIRAL INFECTIONS, OF ORGAN INJURY, AND OF RELATED CONDITIONS USING A HIF PROLYL HYDROXYLASE INHIBITOR OR A HIF-ALPHA STABILIZER | Akebia Therapeutics Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2022251563-A1 | PEDIATRIC FORMULATIONS OF FERRIC CITRATE | KERYX BIOPHARMACEUTICALS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022150623-A1 | COMPOUNDS AND COMPOSITION FOR THE TREATMENT OF ANEMIA | AKEBIA THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2021216530-A1 | TREATMENT OF VIRAL INFECTIONS, OF ORGAN INJURY, AND OF RELATED CONDITIONS USING A HIF PROLYL HYDROXYLASE INHIBITOR OR A HIF-ALPHA STABILIZER | AKEBIA THERAPEUTICS, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-3003284-A1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | Fibrogen, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014197660-A1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | FIBROGEN, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
| WO-2013070908-A1 | THERAPEUTIC METHOD | FIBROGEN, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| EP-2357175-A1 | isoquinoline derivatives AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | Fibrogen, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |